Dade Behring Receives Marketing Clearance for Its Newest Coagulation Analyzer
The Sysmex® CA-560 has received marketing clearance from the US Food and Drug Administration. Designed for lower-volume laboratories, the CA-560 has a compact footprint that enables smaller laboratories to offer specialty testing, including quantitative D-dimer. Additional specialty assays, including heparin anti-Xa to detect the activity of heparin plasma, are also available on the CA-560.
“Even with its convenient smaller footprint, the CA-560 instrument offers features often found only in larger systems,” says Jackie Hauser, marketing manager, Dade Behring Hemostasis. “This new analyzer offers complete random-access testing, with clotting, chromogenic, and immunologic detection simultaneously. With those features, plus the specialty assay capabilities, we can now provide smaller-volume customers with optimal features, all in a compact unit.” She adds that with the addition of the CA-560 to the current family of analyzers, health system instrumentation and result standardization can be achieved.
“This new instrument is the kind of engineering solution that exemplifies the company’s continuous efforts to provide customers with products that meet their real needs,” says Jim Reid-Anderson, chairman, president and CEO, Dade Behring. “It is also the result of our very successful partnering with the Sysmex Corporation in our cooperative efforts to provide customers with incrementally innovative instruments.”
The CA-560 can process up to 60 tests per hour, with capability for five-parameter random access. The analyzer can store data on 300 samples, and has onboard capacity for 60 reaction tube cuvettes. It also features a user-friendly touch screen with bi-directional LIS communication.
